1. Scrip
  2. >>Business
  3. >>Financing

Inventiva Tries Restructuring To Reach Phase III Finish Line In MASH

 
• By Joseph Haas

Large headcount reduction and ending preclinical programs may give Inventiva runway to report Phase III data for lanifibranor that are expected during the second half of 2026.

Inventiva is cutting headcount and ending preclinical R&D to conserve cash (Shutterstock)

After overcoming a financial shortfall in 2024, Inventiva is cutting staff by 50% and ceasing its preclinical research and development efforts to try to make its money last long enough to get Phase III data for its metabolic dysfunction-associated steatohepatitis (MASH) candidate lanifibranor, expected during the second half of 2026.

Key Takeaways
  • With current runway only into Q3 of this year, Inventiva announced a 50% staff cut to get it to the finish line for Phase III data in MASH.

Once viewed as potentially second in line to reach the market with a MASH drug, Inventiva has fallen off that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By Manas Mishra

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Finance Watch: Two New Venture Capital Funds Provide $600m For Biopharma

 
• By Mandy Jackson

Private Company Edition: Catalio raised more than $400m for its fourth health care-focused VC fund, while AN Venture Partners raised $200m for Japan and beyond. In VC financings, among a dearth of mega rounds, Neuron23’s $96.5m series D is the largest round in recent weeks.

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 
• By Andrew McConaghie

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.

More from Therapy Areas

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Moderna’s Spikevax Wins Pediatric Approval, But With Narrower Label

 
• By Alaric DeArment

The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By Kevin Grogan

Lynkuet will compete with Astellas's Veozah/Veoza